Gossamer Bio (GOSS) Interest Expenses (2018 - 2026)
Gossamer Bio (GOSS) posted quarterly Interest Expenses of $5.1 million for Q1 2026, up 87.51% year-over-year from $2.7 million in Q1 2025, and down 14.03% quarter-over-quarter from $6.0 million in Q4 2025.
Gossamer Bio (GOSS) Interest Expenses (2018 - 2026) Analysis & Trends
Gossamer Bio's Interest Expenses history runs 9 years deep, the most recent figure standing at $5.1 million for Q1 2026.
- In Q1 2026, Interest Expenses rose 87.51% year-over-year to $5.1 million; the TTM figure through Mar 2026 stood at $5.1 million (down 61.56% YoY), while the FY2025 annual figure was $273.7 million, up 19.68% from the prior year.
- Interest Expenses for Q1 2026 stood at $5.1 million, down from $6.0 million in the prior quarter.
- The five-year high for Interest Expenses was $65.1 million in Q3 2025, with the low at $2.7 million in Q3 2024.
- The 5-year median for Interest Expenses is $3.5 million (2022), against an average of $7.6 million.
- The sharpest annual moves came in 2023 and 2025: Interest Expenses slumped 42.87% in 2023, then surged 2279.7% in 2025.
- Gossamer Bio's Interest Expenses stood at $5.7 million in 2022, then plunged by 42.87% to $3.2 million in 2023, then soared by 54.37% to $5.0 million in 2024, then advanced by 19.78% to $6.0 million in 2025, then fell by 14.03% to $5.1 million in 2026.
- Business Quant data shows GOSS's Interest Expenses at $5.1 million in Q1 2026, $6.0 million in Q4 2025, and $65.1 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Interest Expense (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 11.00 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | - |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 39.74 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 82.05 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -4.89 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 20.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 93.62 Mn |
| 10 | Gossamer Bio | 49.15 Mn | -7.87 Mn | - | 2.71 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 4.78 Mn |
| Jun 30, 2026 | 4.78 Mn |
| Mar 31, 2026 | 5.15 Mn |
| Mar 31, 2026 | 5.15 Mn |
| Dec 31, 2025 | 5.99 Mn |
| Dec 31, 2025 | 5.99 Mn |
| Sep 30, 2025 | 65.06 Mn |
| Sep 30, 2025 | 65.06 Mn |
| Jun 30, 2025 | 6.73 Mn |
| Jun 30, 2025 | 6.73 Mn |
| Mar 31, 2025 | 2.75 Mn |
| Mar 31, 2025 | 2.75 Mn |
| Dec 31, 2024 | 5.00 Mn |
| Dec 31, 2024 | 5.00 Mn |
| Sep 30, 2024 | 2.73 Mn |
| Sep 30, 2024 | 2.73 Mn |
| Jun 30, 2024 | 2.92 Mn |
| Jun 30, 2024 | 2.92 Mn |
| Mar 31, 2024 | 3.13 Mn |
| Mar 31, 2024 | 3.13 Mn |